Kamada Ltd. (KMDA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.34-0.19 (-4.19%)
As of 9:30 AM EDT. Market open.
People also watch:
EVGNADHDRDHLMZORENZY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.34
Prev Close4.53
Bid4.33 x 1000
Ask4.37 x 400
Day's Range4.34 - 4.34
52wk Range3.26 - 4.57
1y Target EstN/A
Market Cap158.06M
P/E Ratio (ttm)-20.67
Beta1.20
Volume200
Avg Vol (3m)7,301
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Our Take On Kamada Ltd (KMDA)’s Upcoming Catalysts
    Insider Monkey20 days ago

    Our Take On Kamada Ltd (KMDA)’s Upcoming Catalysts

    So we just learnt that development stage biotech company Kamada Ltd (NASDAQ:KMDA) is set to put out topline from a phase II in antitrypsin deficiency before the end of this quarter, and intends to file a biologics licensing application (BLA) with the FDA any time now. It’s going to be a busy couple of months […]

  • Kamada Ltd. :KMDA-IL: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
    Capital Cube20 days ago

    Kamada Ltd. :KMDA-IL: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016

    Categories: Yahoo Finance Click here to see latest analysis Kamada Ltd. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Kamada Ltd. – Compugen Ltd. and RedHill Biopharma Ltd. (CGEN-IL and RDHL-IL) that have also reported for this period. Highlights Summary numbers: Revenues of ILS 72.73 million, ... Read more (Read more...)

  • Associated Press27 days ago

    Kamada reports 2Q loss

    On a per-share basis, the Ness Ziona, Israel-based company said it had a loss of 4 cents. Losses, adjusted for stock option expense, were 3 cents per share. The biopharmaceutical posted revenue of $19.1 ...